NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction; Neostem Will Issue 6.8M Shares, 1.9M Warrants to Buy

NeoStem, Inc. NBS announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc.,  a  development stage cell therapy company focusing on novel treatments for cardiovascular disease. Amorcyte's lead product candidate, AMR-001, is ready to initiate a Phase II study for the  treatment of acute myocardial infarction.